

Antibiotic % Susceptibility Patterns Long-Term Care - Calgary January - December 2022

| LABORATORIES | Data derived from routine susceptibility tests performed by Alberta Precision Laboratories | | | | | | | | | | | | | | | | | | | | | | |
|--|--|------|--------------------------|-------------|-------------------------|-------------------------|-----------------|-----------|----------|-------------|-------------|-------------|-------------------------------|------------|--------------|--------------------------|-----------------------------|------------------------------|-----------------|------------|------------|-----------|-----------|
| Leaders in Laboratory Medicine | | N | Ampicillin / Amoxicillin | Cloxacillin | Amoxicillin-Clavulanate | Piperacillin-Tazobactam | Cephalexin | Cefazolin | Cefixime | Ceftriaxone | Ceftazidime | Clindamycin | Trimethoprim-sulfamethoxazole | Vancomycin | Tetracycline | Doxycycline ^b | Nitrofurantoin ^b | Fosfomycin (PO) ^b | Ciprofloxacin | Gentamicin | Tobramycin | Ertapenem | Мегорепет |
| Gram-positive |] | | | | | | | l . | | | | l . | ļ. | | | | | | l . | | | | |
| Enterococcus faecalis | | 436 | 100 | | | | R | R | R | R | R | R | R | 100 | 27 | | 99 | | 84 ^b | | | | |
| Enterococcus faecium | | 40 | 23 | | | | R | R | R | R | R | R | R | 83 | 38 | | 15 | | 20 ^b | | | | |
| Staphylococcus aureus | All | 217 | | 83 | | | 83 | 83 | | | | 86 | 93 | 100 | 99 | | | | | | | | |
| | MSSA | 182 | | 100 | | | 100 | 100 | | | | 87 | 94 | 100 | 99 | | | | | | | | |
| | MRSA | 38 | | R | | | R | R | | | | 79 | 89 | 100 | 95 | | | | | | | | |
| Gram-negative | 1 | | | | | | | | | | | | | | | | | | | | | | |
| Citrobacter freundii complex ^a | | 39 | R | | R | | R | R | | | | | 95 | | | | 90 | | 82 | 95 | 95 | 100 | 100 |
| Citrobacter koseri | | 30 | R | | 97 | 97 | - ' ' | 100 | 100 | 97 | | | 100 | | | | | | 97 | 100 | 100 | | |
| Enterobacter cloacae complex ^a | | 63 | R | | R | | R | R | 111 | | | | 78 | | | | 37 | | 83 | 98 | 97 | 98 | 100 |
| Escherichia coli | All | 1058 | 55 | | 82 | 85 | 80 ^b | 76 | 82 | 85 | | | 77 | | | | 98 | | 61 | 91 | 91 | | |
| | ESBL | 148 | R | | | | R | R | R | R | R | | 49 | | | 47 | 97 | 98 | 5 | 72 | 73 | 100 | 100 |
| Klebsiella (Enterobacter) aerogenes ^{a,d} | | 46 | R | | R | | R | R | | | | | 100 | | | | 17 | | 93 | 100 | 100 | 98 | 98 |
| Klebsiella oxytoca | | 63 | R | | 92 | 92 | 87 ^b | 62 | 95 | 92 | | | 89 | | | | 92 | | 90 | 94 | 95 | | |
| Klebsiella pneumoniae complex | | 314 | R | | 95 | 97 | 97 ^b | 96 | 97 | 97 | | | 94 | | | | 39 | | 89 | 99 | 100 | | |
| Morganella morganii ^a | | 37 | R | | R | | R | R | | | | | 68 | | | | R | | 59 | 86 | 89 | 100 | 100 |
| Proteus mirabilis | | 300 | 77 | | 98 | 99 | 97 ^b | 75 | 99 | 99 | | | 69 | | R | R | R | | 68 | 95 | 97 | | |
| Providencia species | | 31 | R | | R | | R | R | | | | | 87 | | R | R | R | | 81 | | | 94 | 100 |

R 99

Pseudomonas aeruginosa

Note: Percent susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism recovered from a given patient during the time period analyzed.

Abbreviations: MSSA - methicillin-susceptible Staphylococcus aureus; MRSA - methicillin-resistant Staphylococcus aureus; ESBL - extended spectrum beta-lactamase; R - intrinsic resistance

133

a These organisms usually produce β-lactamase which can cause failure of 3rd generation cephalosporin therapy, despite in vitro susceptibility

^b Urine isolates only

^c Susceptibility to doxycycline can be inferred from susceptibility to tetracycline

^d Combined data (January - December 2021 and January - December 2022) due to the small number of isolates in 2022